Mitochondria, Insulin Resistance, and the Future of Diabetes Treatment
Diabetes Insights - Breakthroughs and InnovatorsShow Notes
In this episode, we meet Prof Gerald Shulman, recipient of this year’s EASD-Novo Nordisk Foundation Diabetes Prize for Excellence, whose pioneering research has reshaped our understanding of insulin resistance and its role in type 2 diabetes and beyond.
Prof. Shulman shares insights from over four decades of research into how ectopic lipid accumulation disrupts insulin signalling, leading to diabetes, fatty liver disease, cardiovascular complications, cancers, and Alzheimer’s disease. He explains how his discoveries - from the role of diacylglycerols to innovative mitochondrial-targeted therapies now in clinical trials - could mark a paradigm shift in the treatment of insulin resistance.
Join us for this inspiring conversation on the future of metabolic medicine and the exciting prospect of treating insulin resistance as a central target for preventing chronic disease.
More from Diabetes Insights - Breakthroughs and Innovators
How does exercise stimulate glucose uptake in muscle and what can this teach us about treating type 2 diabetes?
Prof. Anette-Gabriele Ziegler, this year’s Claude Bernard Prize Lecture recipient, reflects on her career in type 1 diabetes research and the evolution of our understanding of the disease.
The EASD’s first clinical practice guideline on the assessment and management of diabetes distress in adults living with type 1 or type 2 diabetes has now been published in Diabetologia.
How can people living with diabetes help shape the future of diabetes care?
In this episode, Dr Jeroen van der Velde explores one of the most common questions in lifestyle medicine: does the time of day you exercise make a difference?